Login to Your Account

Financings Roundup

Revance Adds $33M for BoNTA Alternative to Botox

By Marie Powers
Staff Writer

Tuesday, April 2, 2013
Revance Therapeutics Inc. raised $33 million in a Series E financing and converted $71 million in convertible debt into Series E preferred stock, aiming to complete U.S. Phase III trials for lead compound RT001, a physician-applied topical botulinum toxin type A, in the lead indication of lateral canthal lines.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription